Amgen’s CETP cholesterol drug Obicetrapib was shelved in 2017 after disappointing results in clinical trials. However, New Amsterdam Pharma has picked up just over a whopping $1 billion in investments for the drug’s revival, largely from the Italian pharma company, the Menarini Group. The investments for the once-dead drug reflect optimism that new metrics for the clinical trial seem promising based on existing data.
According to John Caroll, “They flipped focus from good HDL to bad LDL, where the real benefit lies. And they’re hoping that it will all bear out with a positive pivotal trial now underway, looking to see if the drug can actually reduce key measures of cardio harm — which they say is already reflected in the long-term outcomes for studies that initially reflected only marginally positive advantages for patients.”
To learn more, click here.
(Source: Endpoints News, June 28th, 2022)